A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia

Neuroscience Letters

Volumn 376, Issue 3, 2005, Pages 182-187

  Morita, Yukitaka ^a   Ujike, Hiroshi ^a,b   Tanaka, Yuji ^a,b   Uchida, Naohiko ^a   Nomura, Akira ^a   Ohtani, Kyohei ^a   Kishimoto, Makiko ^a   Morio, Akiko ^a   Imamura, Takaki ^a   Sakai, Ayumu ^a   Inada, Toshiya ^b,c   Harano, Mutsuo ^b,d   Komiyama, Tokutaro ^b,e   Yamada, Mitsuhiko ^b,e   Sekine, Yoshimoto ^b,f   Iwata, Nakao ^b,g   Iyo, Masaomi ^b,h   Sora, Ichiro ^b,i   Ozaki, Norio ^b,h   Kuroda, Shigetoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Japanese Genetics Institute for Drug Abuse   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KURUME UNIVERSITY   (Japan)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^f HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h CHIBA UNIVERSITY   (Japan)

ⁱ TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Methamphetamine dependence psychosis; Nonsynonymous polymorphism; Schizophrenia; The fatty acid amide hydrolase (FAAH); The Pro 129Thr polymorphism

Indexed keywords

ENDOCANNABINOID; FATTY ACID AMIDASE; METHAMPHETAMINE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG DEPENDENCE; ENZYME DEGRADATION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE;

EID: 20844461118     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2004.11.050     Document Type: Article

References (40)

1. L. Arseneault, M. Cannon, R. Poulton, R. Murray, A. Caspi, and T.E. Moffitt Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study Br. Med. J. 325 2002 1212 1213
2. B.F. Cravatt, K. Demarest, M.P. Patricelli, M.H. Bracey, D.K. Giang, B.R. Martin, and A.H. Lichtman Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase Proc. Natl. Acad. Sci. U.S.A. 98 2001 9371 9376
3. B.F. Cravatt, D.K. Giang, S.P. Mayfield, D.L. Boger, R.A. Lerner, and N.B. Gilula Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides Nature 384 1996 83 87
4. B.F. Cravatt, and A.H. Lichtman Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system Curr. Opin. Chem. Biol. 7 2003 469 7475
5. B.F. Cravatt, O. Prospero-Garcia, G. Siuzdak, N.B. Gilula, S.J. Henriksen, D.L. Boger, and R.A. Lerner Chemical characterization of a family of brain lipids that induce sleep Science 268 1995 1506 1509
6. B. Dean, S. Sundram, R. Bradbury, E. Scarr, and D. Copolov Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use Neuroscience 103 2001 9 15
7. W.A. Devane, F.A. Dysarz 3rd, M.R. Johnson, L.S. Melvin, and A.C. Howlett Determination and characterization of a cannabinoid receptor in rat brain Mol. Pharmacol. 34 1988 605 613
8. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, and R. Mechoulam Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1992 1946 1949
9. V. Di Marzo, F. Berrendero, T. Bisogno, S. Gonzalez, P. Cavaliere, J. Romero, M. Cebeira, J.A. Ramos, and J.J. Fernandez-Ruiz Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats J. Neurochem. 74 2000 1627 1635
10. D.K. Giang, and B.F. Cravatt Molecular characterization of human and mouse fatty acid amide hydrolases Proc. Natl. Acad. Sci. U.S.A. 94 1997 2238 2242
11. S. Gonzalez, M.G. Cascio, J. Fernandez-Ruiz, F. Fezza, V. Di Marzo, and J.A. Ramos Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine Brain Res. 954 2002 73 81
12. J.A. Halikas, D.W. Goodwin, and S.B. Guze Marihuana use and psychiatric illness Arch. Gen. Psychiatry 27 1972 162 165
13. A. Johns Psychiatric effects of cannabis Br. J. Psychiatry 178 2001 116 122
14. S. Lamarque, K. Taghzouti, and H. Simon Chronic treatment with delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction Neuropharmacology 41 2001 118 129
15. R.A. Lerner, G. Siuzdak, O. Prospero-Garcia, S.J. Henriksen, D.L. Boger, and B.F. Cravatt Cerebrodiene: a brain lipid isolated from sleep-deprived cats Proc. Natl. Acad. Sci. U.S.A. 91 1994 9505 9508
16. J.T. Leuschner, D.R. Wing, D.J. Harvey, G.A. Brent, C.E. Dempsey, A. Watts, and W.D. Paton The partitioning of delta 1-tetrahydrocannabinol into erythrocyte membranes in vivo and its effect on membrane fluidity Experientia 40 1984 866 868
17. F.M. Leweke, A. Giuffrida, U. Wurster, H.M. Emrich, and D. Piomelli Elevated endogenous cannabinoids in schizophrenia NeuroReport 10 1999 1665 1669
18. J.M. Masserano, F. Karoum, and R.J. Wyatt SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine Behav. Pharmacol. 10 1999 429 432
19. L.A. Matsuda, S.J. Lolait, M.J. Brownstein, A.C. Young, and T.I. Bonner Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 346 1990 561 564
20. P.K. McGuire, P. Jones, I. Harvey, P. Bebbington, B. Toone, S. Lewis, and R.M. Murray Cannabis and acute psychosis Schizophr. Res. 13 1994 161 167
21. J.W. Muschamp, and S.M. Siviy Behavioral sensitization to amphetamine follows chronic administration of the CB1 agonist WIN 55,212-2 in Lewis rats Pharmacol. Biochem. Behav. 73 2002 835 842
22. M. Naassila, O. Pierrefiche, C. Ledent, and M. Daoust Decreased alcohol self-administration and increased alcohol sensitivity and withdrawal in CB1 receptor knockout mice Neuropharmacology 46 2004 243 253
23. I. Racz, A. Bilkei-Gorzo, Z.E. Toth, K. Michel, M. Palkovits, and A. Zimmer A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking J. Neurosci. 23 2003 2453 2458
24. F. Rodriguez de Fonseca, M.R. Carrera, M. Navarro, G.F. Koob, and F. Weiss Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal Science 276 1997 2050 2054
25. M. Sato, C.C. Chen, K. Akiyama, and S. Otsuki Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis Biol. Psychiatry 18 1983 429 440
26. M. Sato, Y. Numachi, and T. Hamamura Relapse of paranoid psychotic state in methamphetamine model of schizophrenia Schizophr. Bull. 18 1992 115 122
27. H.H. Schmid, P.C. Schmid, and V. Natarajan N-Acylated glycerophospholipids and their derivatives Prog. Lipid. Res. 29 1990 1 43
28. J.C. Sipe, K. Chiang, A.L. Gerber, E. Beutler, and B.F. Cravatt A missense mutation in human fatty acid amide hydrolase associated with problem drug use Proc. Natl. Acad. Sci. U.S.A. 99 2002 8394 8399
29. D.J. Spencer Cannabis-induced psychosis Int. J. Addict. 6 1971 323 326
30. G. Tanda, P. Munzar, and S.R. Goldberg Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys Nat. Neurosci. 3 2000 1073 1074
31. E.A. Thomas, B.F. Cravatt, P.E. Danielson, N.B. Gilula, and J.G. Sutcliffe Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system J. Neurosci. Res. 50 1997 1047 1052
32. D.A. Treffert Marijuana use in schizophrenia: a clear hazard Am. J. Psychiatry 135 1978 1213 1215
33. H. Ujike Stimulant-induced psychosis and schizophrenia: the role of sensitisation Curr. Psychiatry Rep. 4 2002 177 184
34. H. Ujike, Y. Morita, Cannabinoid receptors and schizophrenia, J. Pharmacol. Sci., in press.
35. H. Ujike, M. Takaki, K. Nakata, Y. Tanaka, T. Takeda, M. Kodama, Y. Fujiwara, A. Sakai, and S. Kuroda CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia Mol. Psychiatry 7 2002 515 518
36. H. Ujike, and M. Sato Clinical features of sensitization phenomenon observed in patients with methamphetamine dependence and psychosis Ann. N. Y. Acad. Sci. 125 2004 279 287
37. J. Vinklerova, J. Novakova, and A. Sulcova Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251 J. Psychopharmacol. 16 2002 139 143
38. T. Yamaguchi, Y. Hagiwara, H. Tanaka, T. Sugiura, K. Waku, Y. Shoyama, S. Watanabe, and T. Yamamoto Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice Brain Res. 909 2001 121 126
39. S. Zammit, P. Allebeck, S. Andreasson, I. Lundberg, and G. Lewis Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study BMJ 325 2002 1199
40. K. Zavitsanou, T. Garrick, and X.F. Huang Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia Prog. Neuropsychopharmacol. Biol. Psychiatry 28 2004 355 360